MedTrace Logo

Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT03645187 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-04-20

No results posted yet for this study

Summary

The study aimed at evaluation of anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer

Conditions

  • Colon Cancer Stage

Interventions

DRUG

FOLFERI

FOLFERI regimen

DRUG

Folferi and celecoxib

Folferi regimen and celecoxib

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Tarek M Mostafa, Prof · Clinical pharmacy Department- Tanta University

  • Mohamed Alm El-din, prof · Clinical Oncology - Tanta University

  • Amira Roushdy, Msc · Clinical pharmacy Department- Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2025-08-31
Completion
2025-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03645187 on ClinicalTrials.gov